Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma - Motzer, Robert J; Penkov, Konstantin; Haanen, John; Rini, Brian; Albiges, Laurence; Campbell, Matthew T; Venugopal, Balaji; Kollmannsberger, Christian; Negrier, Sylvie; Uemura, Motohide; Lee, Jae L; Vasiliev, Aleksandr; et al. (The New England journal of medicine, 2019)
Keywords: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Apoptosis; Axitinib - administration & dosage; Axitinib - adverse effects; Body weight; Cancer therapies; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - mortality; Drug dosages; Evidence-based medicine; Female; Humans; Immunotherapy; Inhibitor drugs; Kidney cancer; Kidney Neoplasms - drug therapy; Kidney Neoplasms - mortality; Kinases; Male; Middle Aged; Monoclonal antibodies; Oncology; PD-L1 protein; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Progression-Free Survival; Renal cell carcinoma; Single-Blind Method; Sunitinib - adverse effects; Sunitinib - therapeutic use; Survival Rate; Targeted cancer therapy; Tumors; Vascular endothelial growth factor; Germany